You are here: Home » Companies » News
Business Standard

Strides Pharma Science's arm gets USFDA nod to market laxative drug in US

The product will be manufactured at Strides' facility in Bengaluru and will be marketed by Strides Pharma in the US market

Press Trust of India  |  New Delhi 

The company already enjoys a 67-68 per cent share of the respiratory drugs market in India and has potential for a 14-15 per cent growth

Drug firm Strides Pharma Science's subsidiary has received approval from the US health regulator to market laxative 3350 and Electrolytes for Oral Solution.

Strides Pharma Global, Singapore, has received approval for 3350 and Electrolytes for Oral Solution USP in the strengths of 236 grams/2.97 grams/6.74 grams/5.86 grams/22.74 grams/4 Liter from the Food and Drug Administration (USFDA), said in a filing to BSE.

The approved product is a generic version of of

With the current approval, Strides now offers a complete range of PEG 3350 for the US markets comprising of three approved products addressing a combined prescription and OTC opportunity of $400 million as per IMS and IRi data, the company said.

The product will be manufactured at Strides' facility in Bengaluru and will be marketed by Strides Pharma in the US market.

Shares of were trading 1.09 per cent lower at Rs 455 apiece on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Mon, December 24 2018. 11:15 IST
RECOMMENDED FOR YOU